Page 21 - ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article SAN FRANCISCO and SUZHOU, China, July 15, 2021 /PRNewswire/  Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases announced that the first patient has been dosed in a Phase 1a/1b study of IBI319, an anti-PD-1/CD137 bispecific antibody. The objective of this open-label, multi-center Phase 1a/1b dose escalation and expansion study is to evaluate the safety, tolerability, potential optimal dosage and preliminary efficacy of IBI319 in patients with advanced malignant tumors whose cancer progressed on standard-of-care treatment. The trial is being conducted in China.

United statesHong kongInnovent biologicsAdimab incyteEli lillyYilong wuGuangdong lung cancer research instituteMd anderson cancer centerInnovent biologics incClinical developmentIncyte corporationTenured professorGuangdong provincial peopleHonorary directorSenior vice presidentMain board